Vitamin A Reduces Risk of Skin Cancer

According to a recent study, an increased consumption of vitamin A is associated with a decreased risk of squamous cell carcinoma. The second most common form of skin cancer, squamous cell carcinoma arises when an uncontrolled growth occurs in the outermost layer of the skin, called the epidermis. Sun exposure is a huge risk factor of squamous cell carcinoma. This cancer appears as persistent, thick, rough, scaly patches that can bleed. For this study, published in Journal of the American Medica...
Continue reading

Can Artificial Intelligence Diagnose Skin Lesions? With Philipp Tschandl, MD, PhD

​Philipp Tschandl, MD, PhD, and colleagues found that current artificial intelligence (AI) algorithms that use "deep learning"—a type of machine learning that is based on artificial neural networks—outperform humans, even experts, in the classification of pigmented skin lesions. In this interview with i3 Health, Philipp Tschandl, member of the Vienna Dermatologic Imaging Research (ViDIR) Group of the Medical University of Vienna's Department of Dermatology, discusses the significance of the stud...
Continue reading

AI Beats Human Experts in Classifying Skin Lesions

A new study reports that artificial intelligence (AI) in the form of machine-learning algorithms outperforms human experts in the diagnosis of pigmented skin lesions. This web-based study, which was published in The Lancet Oncology, included 511 human readers from 63 countries. Of these, 55.4% were board-certified dermatologists, 23.1% were dermatology residents, and 16.2% were general practitioners. The human readers were asked to diagnose dermatoscopic images that had been randomly selected in...
Continue reading

Rigosertib Provides Hope in Patients With Butterfly Disease

For many patients with the genetic disease recessive dystrophic epidermolysis bullosa (RDEB), also known as butterfly disease, developing squamous cell carcinoma (SCC) by early adulthood is inevitable. Researchers teamed together and found a potential targeted treatment for patients with RDEB and SCC. "We hope that the drug will be a cure for the cancer," remarked one of the authors of the study, Andrew South, PhD, Associate Professor in the Department of Dermatology and Cutaneous Biology at Tho...
Continue reading

Merkel Cell Carcinoma: Pembrolizumab as First-Line Treatment

The second most common cause of skin cancer death, Merkel cell carcinoma (MCC) is a rare and lethal cancer that usually metastasizes quickly. Researchers have discovered that the immunotherapy drug pembrolizumab (Keytruda®), which has already been FDA approved as a second-line treatment for MCC, elicits a better response rate and increased progression-free survival compared with chemotherapy as a first-line treatment for this condition. In this multicenter phase II trial (Cancer Immunotherapy Tr...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.